Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL...10K was last year. Oncology Parma deal...this year!
Billion dollar players are WELL AWARE of Regen's patents and technology!!!
SAN DIEGO, December 1, 2015 /PRNewswire/ --
https://www.prnewswire.com/news-releases/regen-biopharma-inc-attracts-top-researchers-to-scientific-advisory-board-559490921.html
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) today announced that Harry Lander, PhD, currently President of Regen Biopharma, Inc., would also serve as Chief Scientific Officer of the company. Regen also announced that five top researchers have agreed to serve on the company's scientific advisory board. Those researchers are Francesco Marincola, M.D., Ralph Nachman, M.D., Stefano Bertuzzi, Ph.D., Helen Sabzevari, Ph.D. and Lorraine Gudas, Ph.D.
Dr. Lander received a Bachelor of Science degree in biochemistry and a Bachelor of Arts degree in chemistry from State University at Stony Brook in 1987, a doctorate in Biochemistry from Cornell University Graduate School of Medical Sciences in 1992 and an MBA in finance from the New York University Stern School of Business in 2001. Dr. Lander has strong experience as both a researcher and administrator, having served in these positions at Cornell University as well as the Sidra Medical and Research Center in Qatar.
The Regen BioPharma, Inc. scientific advisory board, now numbering 16, will work closely with Dr. Lander and the rest of his management team to advance the firm's small molecule and immuno-oncological therapeutics.
Francesco Marincola, M.D., one of the most recognized tumor immunologists in the world, serves as Chief Research Officer at Sidra Medical and Research Center.
Ralph Nachman, M.D., a renowned hematologist, is a member of the Institute of Medicine and University Professor and former Chairman of Medicine at NY Presbyterian/Weill Cornell Medical Center.
Stefano Bertuzzi, Ph.D., is Executive Director at American Society for Cell Biology and was a senior scientific executive at the National Institutes of Health where he served as Director of Policy and Planning for the Mental Health Institute.
Helen Sabzevari, Ph.D., one of the key leaders in the world in developing immunotherapies, was head of immuno-oncology, global research and early development at MerckSerono.
Lorraine Gudas, Ph.D., is one of the top experts in the world on nuclear receptors and is extremely familiar with the NR2F family of orphan receptors. She is a professor and chairman of the Department of Pharmacology at Weill Cornell Medical College.
"We're putting together a life science dream team," said company Chairman & CEO David Koos. "This is the high-level team we want to shepherd our stem cell and immuno-oncology therapeutics, as well as our novel cancer stem cell therapeutic targets, through development and trials and, ultimately, to the people who need them."
Lander assumes the position of Chief Scientific Officer from Dr. Thomas Ichim, co-founder of Regen BioPharma Inc., who elected to transition to the role of Senior Research Consultant after he and David Koos recruited Dr. Lander as President.
"As the pipeline of the company matures, we need to ensure that we have the right scientific advisors supporting us," said Lander. "Tom is an incredibly creative scientist, and retaining him as our senior research consultant allows us to maintain continuity in our programs and continue to benefit from his remarkable energy and creativity."
False statement?
SAN DIEGO, December 1, 2015 /PRNewswire/ --
https://www.prnewswire.com/news-releases/regen-biopharma-inc-attracts-top-researchers-to-scientific-advisory-board-559490921.html
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) today announced that Harry Lander, PhD, currently President of Regen Biopharma, Inc., would also serve as Chief Scientific Officer of the company. Regen also announced that five top researchers have agreed to serve on the company's scientific advisory board. Those researchers are Francesco Marincola, M.D., Ralph Nachman, M.D., Stefano Bertuzzi, Ph.D., Helen Sabzevari, Ph.D. and Lorraine Gudas, Ph.D.
Accumulating shares at .0175 is like putting money into the BANK!!!
Don't think for a moment that Oil is not in full swing here...
One PR!!!
This is so huge! Life-changing events going on here!
LOL, no money based on what? Official 10K or their Oncology Pharma Homerun? You seemed to leave out that now they have both money and residual income coming from the huge deal! Oh, BTW, that was for only two patents…
From Oncology Parma’s website:
https://www.oncology-pharma.com/
In a further Licensing Agreement, Oncology Pharma has licensed from Regen Biopharma, Inc. an Antigen Specific mRNA Cellular Cancer Vaccine IP for treatment in human pancreatic cancer. The IP entails antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the IP, said modified mRNA encodes peptides derived from the protein surviving. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
Precigen (PGEN) CEO Helen Sabzevari is on RGBP’s Scientific Advisory Board!
PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies.
‘RGBP is making a power house move move up the charts again looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars. RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.082 and its blue skies ahead. RGBP buyout rumors abound; according to many investors It appears there may be a Potential Merger Acquisition looming with Precigen OR another Big Pharma and if so it would make perfect sense for the following reasons. The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccines therapies. https://precigen.com/about. Regenis in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP OR does a Merger Acquisition’
This is a quote from Microcap Daily this past weekend! With today’s 10K, we’re getting ready to explode North!
THIS IS WHY WE’RE HERE!!!
https://www.google.com/amp/s/microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-biotech-sleeper-sitting-on-a-major-league-patent-portfolio/132392/%3famp
Regen BioPharma Inc (OTCMKTS: RGBP) is easily among the most exciting stocks in small caps that has emerged in recent months as one of the most talked about and searched for stocks in the OTC. Currently under heavy accumulation RGBP has been attracting some pretty heavy hitters who see big things in the works here. The stock has a history of explosive moves running to $0.175 earlier this year after the Company and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. RGBP recently broke south of support at $0.013 briefly before heading north off support levels with power signaling to investors the next leg up is upon us. A break over $0.175 and its blue skies ahead for RGBP
Guess what? We’r we broke .0175!
WOW! Not sad at all. THANK YOU for letting us know! RGBP is ready to follow in big footsteps...
Nice post!
Pumping? RGBP is becoming current. No need to pump anything...watch...LOL
Busting through .0182 on our way to .02+?
two million sell at .0182 will be regretted! Watch it fall.
.02 coming today! There is too much here for RGBP not to POP!!!
RGBP bashing almost over....025 this afternoon?
We're going up!
100 million shares just the 1st leg...WOW!!!
You said the same thing Monday...nothing happened except that the PPS went up???
Quote: 'Scammers bailing out...sell when they sell....'
No need to pump 20+ groundbreaking patents says it all! This is happening!
RSI at 54. Could even go down with the PPS going up due to over 100 million shares traded in 3 hours!
Huge churning going on at .018 for the next leg up...
Buys under .02 are incredible. .025 by 1pm???
RGBP put a marker in the ground today! Better get on board!!!
Awesome post aandt!
I believe Regen is getting ready to explode. Since this was written over 6-years ago Regen has over 20 patents now. They now have a partnership!
Your Quote from 6-16-2015: And why is it ridiculous when the company has yet to prove anything while it the CEO has a very troubling history? No cash. No real product. No partnerships. Nada...zilch...zero. And why the pps is where it is. Reality is a bitch, itsn't it?
.007? That has been said for ages now…
Dr. Holcomb, Maverick Energy, Infiniti Energy, Nanogas...none of these folks think amateur hour is going on here...
Why would Nanogas advertise PCTL? Simple and TRUE: They have become partners...
Here’s a real answer:
More details are to be revealed. PCTL is now following through on timelines and transparency. REG D details coming because it is a material event for PCTL.
Maverick joined PCTL in this ‘Disruptive Oil & Gas Technologies Corporation Joint Venture, they also joined with EarthSafe Solutions (Level 2 Distributor) then Maverick Energy became a Level 3 Distributor but to listen to some they would make you think that there is nothing going on. Oh, also, Maverick Hypoclorous Solutions is still there. Oh, also, New Oil Wells being drilled, existing Wells treated…
Don’t listen to the NOISE!!!! Repeat: NOISE! One more time: NOISE!
It only takes one PR for Kaboom…
PCTL has opened a new chapter! On-time PR’s. New CFO & COO in leadership positions. Then, you have someone who feels the need to explain why they have accurately predicted 4 quarters of revenues in a row, then two folks are asked to leave the company…hmmm
PCTL just announced the paying off of warrants! Just announced a REG D to fund huge Oil activities with Maverick Energy. Much much more to come…
30% ride in PPS over the last two weeks is nothing…haven’t even started yet…
Case closed? According to who? Listen folks, great DD here by some! Thank you for posting updates over l even on the weekend!
Negatives everyday??????????????
I have purchased shares in the last two weeks that have risen 30%. Taken for a ride???
Warrants have been cleared and there is no dilution. Reverse split talk is simply to designed for a purpose...
PCTL@PCTL_
58m
Moving forward on Grassy Hill lease
Once the REG D is finished millions will be place for Fluid and Well purchase...PCTL will receive 100% of the fluid sales as their exclusive provider (of course) and a portion of the overall revenues from Oil production, maintenance, etc.
I don't even think this SUB company will be dilutive as a bet big Oil companies will want to invest millions for an ownership position. This will not be small time investors with small time thoughts...
It is dilutive to the SUB company! Not PCTL one bit! Great for PCTL shareholders!